Evogene Subsidiary Casterra Secures $440K Order
Ticker: EVGN · Form: 6-K · Filed: Jun 25, 2024 · CIK: 1574565
Sentiment: neutral
Topics: subsidiary, purchase-order, customer-update
TL;DR
Evogene's Casterra subsidiary just snagged another $440K order from a happy customer.
AI Summary
Evogene Ltd. announced on June 25, 2024, that its subsidiary, Casterra AG Ltd., received an additional purchase order worth approximately $440,000 from an existing customer. This order is detailed in a press release attached to the Form 6-K filing.
Why It Matters
This new purchase order indicates continued business with an existing customer, suggesting customer satisfaction and potential for future growth for Evogene's subsidiary, Casterra.
Risk Assessment
Risk Level: low — The filing is a routine report of a purchase order, not indicating significant financial distress or major strategic shifts.
Key Numbers
- $440,000 — Purchase Order Value (Represents new business secured by Casterra from an existing customer.)
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- Casterra AG Ltd. (company) — Subsidiary of Evogene
- $440,000 (dollar_amount) — Value of purchase order
- June 25, 2024 (date) — Date of announcement
FAQ
What is the nature of the business between Casterra AG Ltd. and the existing customer?
The filing does not specify the nature of the business, only that an additional purchase order was received.
Who is the existing customer that placed the purchase order?
The filing does not disclose the identity of the existing customer.
What is the expected timeline for fulfilling this $440,000 purchase order?
The filing does not provide details on the fulfillment timeline for the purchase order.
Does this purchase order represent a significant portion of Casterra's or Evogene's revenue?
The filing does not provide information to assess the significance of this order relative to overall revenue.
Is this the first purchase order from this customer, or part of a larger ongoing relationship?
The filing states it is an 'additional' purchase order from an 'existing' customer, implying an ongoing relationship.
Filing Stats: 283 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-06-25 07:00:32
Key Financial Figures
- $440,000 — purchase order valued at approximately $440,000 from an existing customer. A copy of th
Filing Documents
- zk2431608.htm (6-K) — 11KB
- exhibit_99-1.htm (EX-99.1) — 14KB
- image00002.jpg (GRAPHIC) — 3KB
- image00003.jpg (GRAPHIC) — 2KB
- 0001178913-24-002068.txt ( ) — 33KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Evogene Ltd., or Evogene, today announces that its subsidiary, Casterra AG Ltd., or Casterra, received an additional purchase order valued at approximately $440,000 from an existing customer. A copy of the press release is attached as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K, or this Form 6-K. This Report of Foreign Private Issuer on Form 6-K, excluding the statements of Casterra's CEO, is incorporated by reference into the registration statements on Form F-3 (File No. 333-277565 ) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215 ) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibits No. 99.1 Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 25, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad —————————————— Yaron Eldad Chief Financial Officer